Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine

Anti-Cancer Drugs

Volumn 10, Issue 6, 1999, Pages 533-536

  Gross, Marine ^b   Hiesse, Christian ^a   Kriaa, Fayçal ^a   Goldwasser, François ^a  

^a HÔPITAL PAUL BROUSSE   (France)

^b FSMSIT Hôpital Paul Brousse ^*

Author keywords

Advanced ovarian cancer; Carboplatin; Gemcitabine; Hemolytic uremic syndrome

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; GEMCITABINE; MITOMYCIN C; PACLITAXEL; TOPOTECAN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; DRUG WITHDRAWAL; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; OVARY CANCER; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032822792     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199907000-00004     Document Type: Article

References (28)

1. 1. Hanna W, Krauss S, Resgestor R, Murphey W. Renal disease after mitomycin C therapy. Cancer 1981; 45: 2583-8.
2. 2. Brain M, Azzopardi J, Baker L, et al. Microangiopathic hemolytic anemia: the role of vascular lesions in pathogenesis. Br J Haematol 1962; 8: 358-74.
3. 3. Snyder HW, Mittelman A, Messerschmidt GL, et al. Treatment of cancer chemotherapy-cssociated thrombotic thrombocytopenia purpura/hemolytic uremic syndrome by Protein A immunoadsorption of plasma. Cancer 1993; 71: 1882-92.
4. 4. Jackson A, Rose B, Graff L, et al. Thrombotic microangiopathy and renal failure associated with antineoplasic chemotherapy. Ann Intern Med 1984; 104: 41-4.
5. 5. Harrel R, Sibley R, Vogelzang N. Renal vascular lesions after chemotherapy with Vinblastine, Bleomycin, and Cisplatinum. Am J Med 1982; 73: 429-33.
6. 6. Aapro MS, Martin C, Hatty S. Gemcitabine - a safety review. Anti-Cancer Drugs 1998; 9: 191-201.
7. 7. Green MR. Gemcitabine safety overview. Semin Oncol 1996; 10: 32-5.
8. 8. Brodowicz T, Breiteneder S, Wiltschke C, Zielinski CC. Gemcitabine-induced hemolytic uremic syndrome: a case report. J Natl Cancer Inst 1997; 89: 1895-6.
9. 9. Krauss S, Sonoda T, Solomon A. Treatment of advanced gastrointestinal cancer with 5-Fluorouracil and Mitomycin C. Cancer 1979; 43: 1598.
10. 10. Okumura H, Nakamura S, Ohtake S, et al. Hemolytic uremic syndrome developing during remission of acute myelomonocytic leukemia. Am J Hematol 1993; 44: 66-7.
11. 11. Ribadi S, Khandekar J, Miller H. Mitomycin-induced hemolytic syndrome: case presentation and review of the literature. Cancer Treat Rep 1982; 66: 1244-7.
12. 12. Lesesne RB, Rothschild N, Erickson B, et al. Cancer associated hemolytic uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989; 7: 781-9.
13. 13. Licciardello JJ, Moake J, Rudy C, et al. Elevated plasma Von Willebrand factor levels and arterial occlusive complication associated with cis-platin based chemotherapy. Oncology 1985; 42: 296-300.
14. 14. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. New Engl J Med 1982; 307: 1432-5.
15. 15. Charba D, Moake JL, Harris MA, Hester J. Abnormalities of von Willebrand factor multimers in drug-associated thrombotic microangiopathies. Am J Hematol 1993; 42: 266-77.
16. 16. Liu K, Mittelman A, Sproal E, Elias E. Renal toxicity in man treated with mitomycin C. Cancer 1971; 28: 1314-20.
17. 17. Jackson AM, Rose BD, Graff LG, Jacobs JB, Schwartz JH, Strauss GM. Thrombotic microangiopathy and renal failure associated with antineoplasic chemotherapy. Ann Intern Med 1984; 101: 41-4.
18. 18. Van der Meer J, de Vries EGE, Vriesendorp R, Willemse PHB, Donker AJM, Aalders JG. Hemolytic uremic syndrome associated with cis-platinum, vinblastine and bleomycin. J Cancer Res Clin Oncol 1985; 110: 119-22.
19. 19. Kambhu SA, Kelsen DP, Fiore J, et al. Metastatic adenocarcinomas of unknown primary site. Am J Clin Oncol 1990; 13: 55-60.
20. 20. Van der Gaast A, Verweij J, Planting ATH, Stoter G. 5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary. Eur J Cancer Clin Oncol 1988; 24: 765-8.
21. 21. Mergenthaler HG, Binsack T, Wilmanns W. Carcinoma-associated hemolytic-uremic syndrome in a patient receiving 5-fluorouracil-adriamycin-mitomycin C combination chemotherapy. Oncology 1988; 45: 11-4.
22. 22. Weinblatt ME, Kahn E, Scimeca PG, Kochen JA. Hemolytic uremic syndrome associated with cisplatin therapy. Am J Pediatr Haematol Oncol 1987; 9: 295-8.
23. 23. Okumura H, Nakamura S, Ohtake S, et al. Hemolytic uremic syndrome developing during remission of acute myelomonocytic leukemia. Am J Hematol 1993; 44: 66-7.
24. 24. Canpolat C, Pearson P, Jaffe N. Cisplatin associated hemolytic uremic syndrome. Cancer 1994; 74: 3059-62.
25. 25. Verwey J, Boven E, van der Meulen J, Pinedo HM. Recovery from mitomycin C induced hemolytic uremic syndrome. A case report. Cancer 1994; 54: 2878-81.
26. 26. Sheldon R, Slaughter D. A syndrome of microangiopathic hemolytic anemia, renal impairment and pulmonary edema in chemotherapy-treated patients with adenocarcinoma. Cancer 1986; 58: 1428-36.
27. 27. Torra R, Poch E, Torras A, Bombi JA, Revert L. Pulmonary hemorrhage as a clinical manifestation of hemolytic uremic syndrome associated with mitomycin C therapy. Chemotherapy 1993; 39: 453-6.
28. 28. Monteagudo J, Pereira A, Roig S, Reverter JC, Ordinas A, Castillo R. Investigation of plasma von Willebrand factor and circulating platelet aggregating activity in Mitomycin C related hemolytic uremic syndrome. Am J Hematol 1990; 33: 46-9.